[Retracted] Peritumor Edema Serves as an Independent Predictive Factor of Recurrence Patterns and Recurrence-Free Survival for High-Grade Glioma

Table 3

The incidence rates of local/marginal/distant recurrence in HGG patients with different clinical parameters.

Characteristics		Local recurrence [ (%)]	Marginal recurrence [ (%)]	Distant recurrence [ (%)]
Gender
Male	38	5, 13.16%	10, 26.32%	23, 60.53%
Female	39	7, 17.95%	10, 25.64%	22, 56.41%
Age (years)
≤50	38	7, 18.42%	9, 23.68%	22, 57.89%
>50	39	5, 12.82%	11, 28.21%	23, 58.97%
WHO pathological grade
III	37	9, 24.32%	8, 21.62%	20, 54.05%
IV	40	3, 7.5%	12, 30%	25, 62.5%
Tumor size
<2 cm	5	0, 0%	1, 20%	4, 80%
2-4 cm	24	7, 29.17%	7, 29.17%	10, 41.67%
>4 cm	48	5, 10.42%	12, 25%	31, 64.58%
Tumor site
FPL	37	5, 13.51%	9, 24.32%	23, 62.16%
TOL	26	2, 7.69%	7, 26.92%	17, 65.38%
BGT	6	1, 16.67%	2, 33.33%	3, 50%
IL	3	0, 0%	1, 33.33%	2, 66.67%
SCB	5	4, 80%	1, 20%	0, 0%
Clinical treatment regimen
Surgery	38	8, 21.05%	11, 28.95%	19, 50%
Surgery+RT/CRT	39	4, 10.26%	9, 23.08%	26, 66.67%
PTE
<1 cm	21	9, 42.86%	5, 23.81%	7, 33.33%
≥1 cm	56	3, 5.36%	15, 26.79%	38, 67.86%
Total	77	12, 15.6%	20, 26%	45, 58.4%

Note: FPL: frontal and parietal lobe; TOL: temporal and occipital lobe; BGT: basal ganglia and thalamus area; IL: insular lobe; SCB: subtentorial cerebellum and brainstem; RT: radiotherapy; CRT: chemotherapy and radiotherapy.